Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimUM-10: Neoadjuvant Darovasertib in Primary Non-metastatic Uveal Melanoma
NCT07015190Phase 3Recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Jan 2026
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of darovasertib in Uveal melanoma (UM), sponsored by IDEAYA Biosciences. Started Jan 2026; status: recruiting.
02
Drugs
darovasertib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07015190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015190.